Bortezomib/Cyclophosphamide/Daratumumab/Dexamethasone Regimen

Preferred Label : Bortezomib/Cyclophosphamide/Daratumumab/Dexamethasone Regimen;

NCIt synonyms : Bortezomib/Cyclophosphamide/Dexamethasone Plus Daratumumab; Bortezomib-Cyclophosphamide-Dexamethasone Plus Daratumumab; Bortezomib/Cyclophosphamide/Dexamethasone Plus Daratumumab Regimen; CyBorD-Daratumumab; VCD-Daratumumab; Bortezomib/Cyclophosphamide/Dexamethasone Plus Darzalex; Bortezomib/Cyclophosphamide/Daratumumab/Dexamethasone; Bortezomib-Cyclophosphamide-Daratumumab-Dexamethasone; Daratumumab-CyBorD; Bortezomib-Cyclophosphamide-Daratumumab-Dexamethasone Regimen;

NCIt definition : A regimen consisting of bortezomib, cyclophosphamide, daratumumab and dexamethasone that can be used for the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis.;

NCI Metathesaurus CUI : CL1664477;

Détails

Origin ID

C181577;

UMLS CUI

C5557635;

Est indiqué pour
- Immunoglobulin Light-chain Amyloidosis [MeSH Descriptor]
Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Bortezomib [NCIt concept]
- Cyclophosphamide [NCIt concept]
- Daratumumab [NCIt concept]
- Dexamethasone [NCIt concept]
concept_is_in_subset
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients